Serum HMGB1 is a potential biomarker for artificial liver treatment in patients with acute liver failure
Life Research · 2026 · 9 (2) · 10
DOI: 10.53388/lr20260010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Research, 2026. Verfasst von Qiu-Yan Zhao und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Background
High-mobility group box 1 (HMGB1) is a critical damage-associated molecular pattern protein that participates in diverse physiological and pathological processes. However, its relevance to the prognosis of artificial liver support therapy in patients with acute liver injury (ALF) remains unclear.
Methods
Bioinformatics analyses were performed to identify HMGB1-interacting proteins and associated inflammatory signaling pathways. Peripheral blood samples were collected from ALF patients before and after artificial liver support therapy, and serum HMGB1 concentrations were quantified using ELISA. Primary mouse hepatocytes were stimulated with lipopolysaccharide (LPS) in vitro and HMGB1 expression was verified by western blot.
Results
Single-cell transcriptomic profiling showed that HMGB1 is widely expressed across tissues and predominantly localized in the nucleus. In the liver, HMGB1 was primarily expressed in hepatocytes and hepatic stellate cells. STRING database analysis revealed that human HMGB1 interacts with multiple proteins, including TLR4, TP53, and BECN1. The constructed interaction network comprised 11 nodes with an average local clustering coefficient of 0.888, and the protein–protein interaction enrichment P -value was 1.42 × 10 −5 , indicating significant enrichment. Gene Ontology and KEGG pathway enrichment analyses demonstrated that HMGB1 is closely linked to inflammatory and injury-related signaling pathways, including the TLR and NLR pathways. Metabolomic profiling revealed significant metabolic alterations between patients with ALF and healthy controls under both positive and negative ion modes and functional analysis showed necroptosis was activated. The cell viability gradually decreased with time and dose under LPS treatment and extracellular HMGB1 was upregulated in LPS induced ALF model and patients ( P < 0.05). Serum HMGB1/RIPK3/MLKL levels were markedly elevated in ALF patients compared with controls ( P < 0.05) and progressively declined following artificial liver support therapy. Furthermore, elevated HMGB1 concentrations were positively correlated with unfavorable clinical outcomes.
Conclusion
Peripheral blood HMGB1 levels are significantly increased in patients with acute liver failure, decrease following artificial liver support therapy, and are positively associated with poor clinical prognosis.
Zitieren
APA
Zhao, Q., Liu, S., Zuo, Z., Li, Z., Xu, J., Yin, C., Li, H., Zhu, L., Li, C., Zhang, H., Qian, L., Qi, J., Song, Z., Ni, D., & Tang, Y. (2026). Serum HMGB1 is a potential biomarker for artificial liver treatment in patients with acute liver failure. Life Research, 9(2), 10. https://doi.org/10.53388/lr20260010
Vancouver
Zhao Q, Liu S, Zuo Z, Li Z, Xu J, Yin C, et al. Serum HMGB1 is a potential biomarker for artificial liver treatment in patients with acute liver failure. Life Research. 2026;9(2):10. doi:10.53388/lr20260010
BibTeX
@article{Zhao2026,
author = {Zhao, Qiu-Yan and Liu, Shu-Jing and Zuo, Zan and Li, Zuo-Yong and Xu, Juan and Yin, Chun-Ping and Li, Hong-Na and Zhu, Li-Na and Li, Chun-Fang and Zhang, Hui-Ming and Qian, Lin-Ling and Qi, Jia-Long and Song, Zheng-Ji and Ni, Dan-Rong and Tang, Yuan},
title = {Serum HMGB1 is a potential biomarker for artificial liver treatment in patients with acute liver failure},
journal = {Life Research},
year = {2026},
volume = {9},
number = {2},
pages = {10},
doi = {10.53388/lr20260010}
}
EUVIMED